Menten AI

Menten Biotechnology Labs - also known as Menten AI - is a company that develops new protein therapeutics for drug development through the use of machine learning and quantum computing. It was founded in 2018 by Hans Melo, Vikram Mulligan, and Tamas Gorbe. Menten Biotechnology Labs is headquartered in San Francisco, California, United States. It has received funding from investors such as Uncork Capital, Founders X, and Khosla Ventures. Menten Biotechnology was a cohort of Y Combinator's W20.

Menten Biotechnology Labs - also known as Menten AI - is a company that develops new protein therapeutics for drug development through the use of machine learning and quantum computing. It was founded in 2018 by Hans Melo, Vikram MulliganVikram Mulligan, and Tamas Gorbe. Menten Biotechnology Labs is headquartered in San Francisco, California, United States. It has received funding from investors such as Uncork Capital, Founders X, and Khosla Ventures. Menten Biotechnology was a cohort of Y Combinator's W20.

Menten Biotechnology Labs - also known as Menten AI - is a company that develops new protein therapeutics for drug development through the use of machine learning and quantum computing. It was founded in 2018 by Hans MeloHans Melo, Vikram Mulligan, and Tamas Gorbe. Menten Biotechnology Labs is headquartered in San Francisco, California, United States. It has received funding from investors such as Uncork Capital, Founders X, and Khosla Ventures. Menten Biotechnology was a cohort of Y Combinator's W20.

Menten Biotechnology Labs - also known as Menten AI - is a company that develops new protein therapeutics for drug development through the use of machine learning and quantum computing. It was founded in 2018 by Hans Melo, Vikram Mulligan, and Tamas Gorbe. Menten Biotechnology Labs is headquartered in San FranciscoSan Francisco, California, United States. It has received funding from investors such as Uncork Capital, Founders X, and Khosla Ventures. Menten Biotechnology was a cohort of Y Combinator's W20.